Argos files for second IPO
DURHAM – Argos Therapeutics Inc., a Durham-based biopharmaceutical company that’s working to develop a kidney cancer treatment, is looking to raise $60 million in an initial public offering of stock, according to a registration document filed with the U.S. Securities and Exchange Commission.
The company is planning to use the money to help fund clinical trials of the treatments it’s developing for kidney cancer and for HIV, as well as to start the planned leasing, build-out and equipment for a new commercial manufacturing facility and for capital and general corporate costs.
This will be the second initial public offering filed by the company following another filed initially in 2011, and withdrawn in March of 2012.
The company’s treatments are being developed using a technology that uses biological components from a patient’s own cancer cells or virus to generate personalized therapies that use specialized white blood cells called dendritic cells to activate an immune response specific to the patient’s own disease.